15 July 2024
Ropes & Gray Advises Amylyx Pharmaceuticals in Acquisition of Phase 3-Ready Asset from Eiger BioPharmaceuticals
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Hannah England | Ropes & Gray | Partner | life sciences licensing | Not stated |
| Cristi Schwarzman | Ropes & Gray | Partner | business restructuring | Not stated |
| Scott Pinarchick | Ropes & Gray | Partner | tax | Not stated |
| Kellie Combs | Ropes & Gray | Partner | life sciences regulatory & compliance | Not stated |
| Eve Brunts | Ropes & Gray | Partner | health care | Not stated |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 35.1m ($35.1 million)
- What the figure measures
- Total transaction value
- Client
- Amylyx PharmaceuticalsBuy-side
- Counterparties
- Eiger BioPharmaceuticals (Sell-side)